Late-Breaking from ASH22 – Let’s Keep the Standard Consolidation Therapy with HDC-ASCT for PCNSL Patients
The first results from the MATRix/IELSG43 trial indicate that standard consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation results in significantly better outcomes when compared to non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
